Prime editing, introduced by David Liu’s group at the Broad Institute in 2019, combined a catalytically impaired Cas9 nickase with an engineered reverse transcriptase and a guide RNA that carries both the targeting information and the template for the desired edit. The system writes new sequence directly into the genome without making a full double-strand break, avoiding the chaotic repair outcomes that plague conventional CRISPR-Cas9 cutting. Yet prime editing has always faced a ceiling: the efficiency and precision of the approach decline sharply as the requested edit grows larger. Insertions of more than a few dozen base pairs become unreliable, and integrating entire genes or rearranging chromosome segments has remained largely out of reach.

Prime assembly tackles that ceiling by reconceiving the edit as a stepwise construction process rather than a single copying event. Instead of forcing the reverse transcriptase to polymerize a long, unwieldy DNA tract in one continuous reaction, the system orchestrates a series of coordinated sub-edits, each installing a defined fragment at the target locus. Because each fragment is short enough to be written with high fidelity, the assembled product can extend to kilobase scale while maintaining the sequence accuracy that defines prime editing. The design encodes overlapping junctions within the delivered template RNAs so that successive fragments anneal to one another and to the genomic target, stitching the pieces into a contiguous, correctly ordered insert.

The molecular choreography relies on a redesigned editing complex. The researchers report engineering the prime editor apparatus and its guide RNA architecture so that multiple template modules can be loaded and processed in a defined sequence at the same target site. Timing and polarity matter enormously in genome writing: a fragment installed out of order, or in the wrong orientation, would leave behind scars or truncate the intended product. The prime assembly system addresses this by controlling the order in which template segments are reverse-transcribed and by using nicking patterns that favor progressive extension of the nascent strand. In effect, the genome itself becomes the scaffold on which the new sequence is assembled, and the cell’s own repair machinery seals the final junctions.

What distinguishes the work most sharply from earlier large-insert methods is the degree of control over rearrangement. Transposon-based delivery systems can move large cargoes but do so at their own preferred genomic sites, and double-strand-break-dependent methods such as CRISPR paired with homologous recombination or non-homologous end joining frequently generate a messy mixture of deletions, inversions, and random integrations. Prime assembly, by contrast, specifies both the landing site and the structure of the rearrangement. The paper demonstrates targeted integration of sizable genetic payloads, precise excision of unwanted segments, and programmable reorganization of DNA segments within a locus, all without introducing a double-strand break at any point in the procedure.

The technical benchmarks reported in the study emphasize both efficiency and purity. Across the demonstrated edit classes, the authors describe insertion products that are predominantly exact, with detectable byproducts reduced relative to break-dependent alternatives. Sequence-level analysis of the assembled products shows the expected junction architecture, an important indicator that the overlapping-fragment design behaves as intended rather than relying on stochastic recombination. Editing outcomes were profiled at the DNA level with deep sequencing and, for the larger rearrangements, with long-read sequencing capable of confirming the structure of multi-kilobase changes end to end, a level of verification that smaller-scale editing studies rarely require.

The implications for disease research are considerable. A large fraction of pathogenic mutations are not simple point substitutions. Thousands of known genetic disorders arise from deletions, duplications, insertions of mobile elements, or larger structural changes that conventional single-nucleotide editors cannot address. Gene-addition therapies using viral vectors can deliver a working copy of a gene, but they insert it at a semi-random safe-harbor location rather than restoring the native locus, losing native regulation and occasionally provoking insertional complications. Prime assembly offers a route to writing a functional gene back into its endogenous position, complete with its own regulatory context, or to rebuilding a damaged locus from the bottom up.

Synthetic genome engineering stands to benefit even more directly. Building entire chromosomes and synthetic genomes has so far depended on laborious cycles of homologous recombination in yeast or on assembly in vitro followed by transplantation, approaches that are slow and species-limited. A method that can integrate large designed sequences at user-chosen genomic addresses in mammalian or other difficult cells would compress that workflow dramatically. The authors’ demonstration of programmable rearrangement suggests a longer-term vision in which genome architecture itself, not merely gene sequence, becomes an editable design parameter, allowing researchers to test in weeks what once took years of strain construction.

As with every genome-editing advance, the distance between a demonstration in cultured cells and a therapeutic reality is substantial. Delivery remains the field’s perennial bottleneck: prime editors are large multi-component systems, and a prime assembly platform that carries multi-part template cargoes is larger still, making efficient in vivo delivery a formidable engineering problem in its own right. Off-target activity, immunogenicity of the bacterial-derived editor proteins, and the long-term stability of large engineered loci will all need rigorous assessment. The authors and the field more broadly will also need to establish how the method performs in primary cells, tissues, and whole organisms, where chromatin context and cell-cycle state strongly influence repair outcomes.

Even with those caveats, prime assembly represents a conceptual milestone in the transition of genome editing from correction to construction. The first decade of CRISPR made cutting routine; the second made precise rewriting of individual letters increasingly reliable. Prime assembly points toward a third phase in which geneticists can move, add, and reorganize whole stretches of the genome with the same programmability that made base editing famous. For patients with structural variants that no current therapy can touch, and for engineers attempting to build genomes to specification, the ability to assemble DNA in place, fragment by fragment, at the exact location of choice, may prove to be one of the more consequential ideas to emerge from the genome-writing field in years.

Subject of Research: Prime assembly genome editing for targeted DNA integration and rearrangement

Article Title: Targeted genomic integration and rearrangement using prime assembly

Article References: Levesque, S., Kawashima, N., Hwang, G.-H., Zeng, J., Toskov, V., Barry, T., Mannherz, W., Homfeldt, L., Becerra, B., Schoonenberg, V. A. C., Pinello, L., Agarwal, S., & Bauer, D. E. (2026). Targeted genomic integration and rearrangement using prime assembly. Nature. https://doi.org/10.1038/s41586-026-11024-2

Image Credits: AI Generated

DOI: 10.1038/s41586-026-11024-2

Keywords: prime assembly, prime editing, genome editing, gene writing, CRISPR, reverse transcriptase, DNA integration, structural variants, synthetic genomics, gene therapy, molecular biology, biotechnology

The work addresses a gap that has shaped the trajectory of genome engineering for more than a decade. Since the advent of programmable nucleases, researchers have been able to direct double-strand breaks to almost any chosen sequence, and cellular repair machinery can sometimes stitch in a new DNA cassette at the break site. But that approach leans on the cell’s own repair pathways, which are error-prone, unpredictable and often disabling to the very sequences scientists want to insert. Broken DNA is dangerous DNA, and cells treat integration events as injuries to be patched rather than as opportunities for precise reconstruction.

Prime editing, first described in 2019, took a fundamentally different route. Rather than cutting both strands of the DNA double helix, a prime editor pairs a Cas9 nickase — an engineered enzyme that cuts only one strand — with an engineered reverse transcriptase. The editing instructions are carried on a prime editing guide RNA, or pegRNA, which both locates the target site and encodes the new genetic information the reverse transcriptase should write into the nicked strand. Because the process avoids double-strand breaks and does not require an additional donor DNA template supplied in bulk, prime editing has proven remarkably clean for small substitutions, insertions and deletions.

Where prime editing has historically faltered, however, is scale. The reverse transcriptase copies a sequence encoded within the pegRNA itself, and practical constraints on RNA length, delivery and synthesis efficiency have limited the size of the DNA payload that a single prime-editing event can install. For applications in which a functional gene, a large regulatory element or a multi-kilobase cassette must be placed at a defined genomic address, the technology’s ceiling has been a persistent frustration. Complementary systems — including CRISPR-associated transposases and integrase-based platforms — can move larger cargoes, but they typically bring their own constraints on target-site selection, orientation and cargo compatibility.

The new study, led by researchers working at the interface of protein engineering and genome technology, tackles the size problem by rethinking how the donor DNA participates in the reaction. In the reported strategy, termed donor-directed annealing, the genetic cargo is carried on a separate donor molecule rather than being encoded within the pegRNA. The prime editor still performs its characteristic task of opening the target site and synthesizing an exposed stretch of new DNA on the nicked strand, but that newly synthesized sequence is designed to serve as a molecular landing pad. Once exposed, it is complementary to sequences at the end of the donor fragment, and the two single-stranded regions find each other and anneal, drawing the donor cargo into the editing site.

The elegance of the design lies in what happens next. Cellular DNA repair enzymes process the annealed intermediate, ligating the donor fragment into the genome through the natural resolution of the flap-like structure that the prime editor has created. Because the specificity of the event is dictated by sequence complementarity between the editor-generated overhang and the donor terminus, the cell is never asked to recognize a double-strand break or to improvise an end-joining reaction. The authors report that this mechanism allows fragments substantially larger than the payloads accessible to conventional prime editing to be incorporated at defined loci, with precision determined largely by the programmed overlap rather than by stochastic cellular repair.

From a biochemical standpoint, donor-directed annealing converts what has been an intramolecular copying reaction into a hybridization-guided assembly step. Conventional prime editing is, in essence, a controlled form of DNA synthesis: the pegRNA templates every base that the reverse transcriptase installs. The new method retains that templated synthesis for a short anchoring sequence but delegates the bulk of the payload to a separate donor, which can be produced synthetically or by standard cloning at lengths far beyond what a pegRNA can encode. The trade-off is that the donor and the pegRNA must be co-delivered and their sequences coordinated, but the payoff is a system in which cargo size is no longer bound to the physical limits of the guide RNA.

The practical implications extend across both research and therapeutic arenas. In basic biology, the ability to drop large regulatory modules, reporter constructs or engineered gene circuits into precise genomic contexts would simplify experiments that currently require laborious screening of random integration events. In medicine, many inherited disorders are caused by mutations in genes that are too large, too structurally complex or too mutationally diverse to be addressed base by base. Delivering a corrected copy of a gene, or a functional cDNA, into its native locus under the control of endogenous regulatory elements — rather than scattering it randomly through the genome as viral vector gene therapy does — remains the aspirational gold standard, and integration strategies of this kind are among the most credible paths toward it.

The reported system also speaks to a recurring theme in the genome-editing literature: the value of avoiding double-strand breaks altogether. Studies across multiple cell types have associated double-strand-break-based editing with p53 activation, chromosomal rearrangements and large unintended deletions, concerns that are particularly acute for ex vivo cell therapies and in vivo applications alike. By building integration on a nicking enzyme and sequence-programmed annealing rather than on blunt-ended break repair, the approach aligns with the field’s broader movement toward editing chemistries that leave the genome’s integrity machinery largely undisturbed.

As with any genome-engineering advance, several questions will shape how the technique matures. The efficiency of integration across different genomic loci, cell types and species will need systematic mapping; cargo lengths will have practical ceilings set by delivery vehicles rather than by chemistry; and off-target activity — a concern for any nuclease-fusion system — will require careful characterization at both the sequence and chromosomal level. The study’s authors report encouraging precision at the sites they examined, and the strategy’s dependence on designed sequence complementarity offers a built-in specificity checkpoint that many integration methods lack. Independent replication and optimization in therapeutically relevant primary cells will be the next milestones.

What the work illustrates most clearly is how quickly the conceptual boundaries of genome editing continue to move. In barely a decade, the field has progressed from cutting DNA at chosen addresses, to rewriting individual letters of the genetic code, to contemplating the programmed installation of whole functional modules at will. Donor-directed annealing extends prime editing’s core strengths — precision, minimized DNA damage and programmability — into a size regime that those strengths had not previously reached. If the method’s efficiency and reliability hold up as it is tested more broadly, large-fragment insertion could shift from a heroic, low-yield exercise to a routine operation in the genome engineer’s toolkit, with consequences for drug discovery, synthetic biology and, ultimately, the treatment of diseases that small edits alone cannot fix.

Subject of Research: Precise integration of large DNA fragments into genomic target sites using prime editing with donor-directed annealing

Article Title: Precise genomic integration of large DNA fragments by donor-directed annealing using prime editing

Article References: Jung, H., Jeong, B., Kim, Y.-W., Jung, C., Lee, S., Uhm, H., Kim, H., Oh, Y. E., Park, Y., Lee, Y., Kang, M., Im, H. W., Kim, D., Lee, S., Kim, Y., Choi, K., & Bae, S. (2026). Precise genomic integration of large DNA fragments by donor-directed annealing using prime editing. Nature Biotechnology. https://doi.org/10.1038/s41587-026-03301-2

Image Credits: AI Generated

DOI: 10.1038/s41587-026-03301-2

Keywords: prime editing, genome editing, CRISPR, gene therapy, DNA integration, pegRNA, reverse transcriptase, Cas9 nickase, large DNA fragments, donor-directed annealing, biotechnology, genetic engineering